TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8630575

Group type: EXPERIMENTAL
Intervention: 600 mg zileuton, a 5-lipoxygenase inhibitor
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2006743

Group type: EXPERIMENTAL
Intervention: 240 mL water
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 240 mL coffee
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 240 mL pulp-free orange juice
Number of subjects: 30
Study: 7129722

Group type: EXPERIMENTAL
Intervention: 10:20 regimen (35 10‐s maximal isometric contractions separated by a 20‐s rest)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 10:5 regimen (35 maximal isometric contractions separated by 5 s between trials)
Number of subjects: 11
Study: 31760820

Group type: EXPERIMENTAL
Intervention: CPVI started with right pulmonary veins at RAGP site (group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: CPVI started with left pulmonary veins first, last ablation site is RAGP (group B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 80
Study: 28961737

Group type: EXPERIMENTAL
Intervention: Miltefosine monotherapy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Miltefosine combination therapy
Number of subjects: 95
Study: 25428627

Group type: EXPERIMENTAL
Intervention: 5% lidocaine patches
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 36
Study: 25141535

Group type: EXPERIMENTAL
Intervention: Isolated and co-contraction training of trunk stabilizers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (resting comfortably on a chair)
Number of subjects: 0
Study: 21934585

Group type: EXPERIMENTAL
Intervention: Mobile Compression Device (MCD)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Low-Molecular-Weight Heparin (LMWH)
Number of subjects: 395
Study: 19377147

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) distraction technique provided through a cell phone connected to an HMD
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-distraction control condition
Number of subjects: 0
Study: 17410417

Group type: EXPERIMENTAL
Intervention: Oral opioid blockade
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 15704589

Group type: EXPERIMENTAL
Intervention: Xuesaitong Injection, i.v., once a day for 14 days
Number of subjects: 86

Group type: COMPARATOR
Intervention: Routine therapy with western medicine (Control)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Xuesaitong Injection
Number of subjects: 86
Study: 11437674

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Standard immunosuppressive protocols (cyclosporin and corticosteroids)
Number of subjects: 1500
Study: 9257765

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg administered at 1000 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg administered at 2200 hours
Number of subjects: 12
Study: 7693424

Group type: EXPERIMENTAL
Intervention: Tamoxifen 30 mg/day orally for 3 years (Group A, n = 192)
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: FEC 50 for 6 cycles (Group B, n = 183)
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: Tamoxifen 30 mg/day orally for 3 years plus FEC 50 for 6 cycles (Group C, n = 182)
Number of subjects: 741

Group type: COMPARATOR
Intervention: No medical adjuvant treatment (Group D, n = 184)
Number of subjects: 741
Study: 3121334

Group type: EXPERIMENTAL
Intervention: rt-PA + heparin
Number of subjects: 68

Group type: COMPARATOR
Intervention: placebo + heparin
Number of subjects: 68
Study: 30904867

Group type: EXPERIMENTAL
Intervention: Mother and Baby Units (MBUs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generic acute psychiatric wards
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crisis Resolution Teams (CRTs)
Number of subjects: 0
Study: 28636851

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg IV every 2 weeks)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Chemotherapy (platinum-based, administered once every 3 weeks for up to six cycles)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 423

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 423
Study: 26289514

Group type: EXPERIMENTAL
Intervention: Hibiscus sabdariffa (HS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 23432779

Group type: EXPERIMENTAL
Intervention: Dressing removed on postoperative day one
Number of subjects: 200

Group type: COMPARATOR
Intervention: Dressing removed on postoperative day six
Number of subjects: 200
Study: 20336685

Group type: EXPERIMENTAL
Intervention: Thermal exercise protocol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control condition (nonthermal exercise)
Number of subjects: 10
Study: 20374312

Group type: COMPARATOR
Intervention: CLAs 2.5 g
Number of subjects: 87

Group type: COMPARATOR
Intervention: Vitamin E 400 mg
Number of subjects: 87

Group type: COMPARATOR
Intervention: CLAs and Vitamin E
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 17598577

Group type: EXPERIMENTAL
Intervention: Active eye-tracking on (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Active eye-tracking off (n = 25)
Number of subjects: 50
Study: 15107507

Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 80
Study: 12204708

Group type: EXPERIMENTAL
Intervention: latanoprost 0.005% in the evening
Number of subjects: 2

Group type: COMPARATOR
Intervention: timolol 0.5% twice daily
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: latanoprost 0.005% adjunctively
Number of subjects: 2
Study: 9612832

Group type: EXPERIMENTAL
Intervention: Structured advice from physician and referral to individual behavior change counseling during prenatal care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brief advice to stop smoking and a quit smoking booklet at first visit (usual care)
Number of subjects: 0
Study: 7924168

Group type: EXPERIMENTAL
Intervention: Ethanol (1g/kg body weight)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Juice (control)
Number of subjects: 12
Study: 2571386

Group type: EXPERIMENTAL
Intervention: Sulphasalazine (SAS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 53370

Group type: EXPERIMENTAL
Intervention: Group-A polysaccharide vaccine
Number of subjects: 16458

Group type: COMPARATOR
Intervention: Control (not vaccinated)
Number of subjects: 16458
Study: 31365184

Group type: EXPERIMENTAL
Intervention: PTSD patients
Number of subjects: 152

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 152
Study: 27761791

Group type: EXPERIMENTAL
Intervention: Probiotics (L. acidophilus, L. rhamnosus, and L. sporogenes)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 25879008

Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg (group A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg (group B)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sugammadex 2 mg/kg (group A) and Sugammadex 4 mg/kg (group B)
Number of subjects: 32
Study: 23444169

Group type: EXPERIMENTAL
Intervention: Diflunisal-Naproxen fixed-dose combination (FDC) tablet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Co-administration of two separate diflunisal and naproxen marketed tablets
Number of subjects: 24
Study: 21120461

Group type: EXPERIMENTAL
Intervention: Extended-release niacin 1000 mg/day for 2 days, followed by 2000 mg/day for 5 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin 10 mg/20 mg/day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Coadministration of extended-release niacin and ezetimibe/simvastatin
Number of subjects: 18
Study: 20110026

Group type: EXPERIMENTAL
Intervention: Barnidipine (10-20 mg once daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (normotensive subjects)
Number of subjects: 21
Study: 17275927

Group type: EXPERIMENTAL
Intervention: Unilateral cochlear implant turned on
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Unilateral cochlear implant turned off
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standing on foam with closed eyes (Condition 2)
Number of subjects: 36
Study: 15533270

Group type: EXPERIMENTAL
Intervention: Substitution of high‐fat foods with reduced‐fat products
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Reduction of high‐fat foods
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination of substitution and reduction strategies
Number of subjects: 80

Group type: COMPARATOR
Intervention: No advice given
Number of subjects: 80
Study: 11322357

Group type: EXPERIMENTAL
Intervention: Thyroxine therapy for subclinical hypothyroidism with TSH > 10 mIU/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individualized decision for therapy for subclinical hypothyroidism with TSH between 5 and 10 mIU/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment for subclinical hyperthyroidism
Number of subjects: 0
Study: 9491823

Group type: EXPERIMENTAL
Intervention: CP-105,696 (5 to 640 mg single oral dose)
Number of subjects: 48
Study: 7819683

Group type: EXPERIMENTAL
Intervention: Airway opening sensors
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Inspiratory pressure transducers
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Expiratory pressure transducers
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Graseby capsule
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Strain gauges
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Oesophageal pressure
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional apnoea monitor
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Total delay for airway sensors in severe lung disease
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Total delay for airway sensors in near normal infants
Number of subjects: 36
Study: 2512163

Group type: EXPERIMENTAL
Intervention: Antibiotics (mainly ampicillin and netilmicin)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Adapted cow's milk formula with lard
Number of subjects: 36
Study: 1180124

Group type: EXPERIMENTAL
Intervention: Phenobarbital 100 mg daily for 7 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diazepam 15 mg daily for 7 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oxazepam 75 mg daily for 7 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Baseline values
Number of subjects: 24
Study: 31769500

Group type: EXPERIMENTAL
Intervention: ThinPrep automated method (TPAM)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: ThinPrep manual method (TPMM)
Number of subjects: 1500
Study: 31320177

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC)/azathioprine (AZA)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 78
Study: 29515726

Group type: EXPERIMENTAL
Intervention: 5 mg hypobaric bupivacaine
Number of subjects: 108

Group type: COMPARATOR
Intervention: 7.5 mg hypobaric bupivacaine
Number of subjects: 108
Study: 26287302

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 60
Study: 23453104

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 5745

Group type: COMPARATOR
Intervention: Baseline risk factors
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: Dynamic risk models
Number of subjects: 5745
Study: 16143706

Group type: EXPERIMENTAL
Intervention: Aspirin plus warfarin (A+W)
Number of subjects: 25307

Group type: EXPERIMENTAL
Intervention: Aspirin plus warfarin (A+W) with INR of 2-3
Number of subjects: 25307
Study: 15058044

Group type: EXPERIMENTAL
Intervention: Incremental cycling exercise test after blood donation (450 ml)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control study (before blood donation)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control study
Number of subjects: 13
Study: 10355400

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Papaverine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Linsidomine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 50
Study: 8686260

Group type: EXPERIMENTAL
Intervention: French measles vaccine
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Japanese measles vaccine
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Russian measles vaccine
Number of subjects: 181
Study: 1822966

Group type: EXPERIMENTAL
Intervention: Very high purity concentrate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intermediate purity concentrate
Number of subjects: 20
Study: 7150898

Group type: EXPERIMENTAL
Intervention: 3F/week radiotherapy
Number of subjects: 706

Group type: COMPARATOR
Intervention: 5F/week radiotherapy
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Sub-groups with highly localized tumours
Number of subjects: 706
Study: 31060605

Group type: EXPERIMENTAL
Intervention: Appropriate management of malaria cases in Zambézia (52%, 95% CI 42-62)
Number of subjects: 1840

Group type: EXPERIMENTAL
Intervention: Appropriate management of malaria cases in Cabo Delgado (49%, 95% CI 42-57)
Number of subjects: 1840

Group type: EXPERIMENTAL
Intervention: Appropriate management of malaria cases in Maputo Province (14%, 5-34)
Number of subjects: 1840

Group type: EXPERIMENTAL
Intervention: Testing of febrile patients in Maputo Province (46%)
Number of subjects: 1840

Group type: EXPERIMENTAL
Intervention: Anti-malarial treatment of patients with negative malaria test in Maputo Province (8%, 2-23)
Number of subjects: 1840

Group type: EXPERIMENTAL
Intervention: Anti-malarial treatment of patients with negative malaria test in Zambézia (22%, 14-32)
Number of subjects: 1840

Group type: EXPERIMENTAL
Intervention: Correct recitation of dosing instructions for anti-malarial treatment (58-62%)
Number of subjects: 1840
Study: 28264130

Group type: EXPERIMENTAL
Intervention: RGTA eye drops
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (identical medical agents postoperatively)
Number of subjects: 60
Study: 26621819

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg plus omeprazole 40 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Omeprazole 40 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Ranitidine 300 mg
Number of subjects: 21
Study: 24321717

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 10
Study: 21519556

Group type: EXPERIMENTAL
Intervention: Composite alloplast with open flap debridement
Number of subjects: 10

Group type: COMPARATOR
Intervention: Open flap debridement alone (Control)
Number of subjects: 10
Study: 18285439

Group type: COMPARATOR
Intervention: Experimental treatments
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard treatments
Number of subjects: 20
Study: 16702841

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14530751

Group type: EXPERIMENTAL
Intervention: Self-help rehabilitation manual plus ward visits, three telephone calls at home, and clinic appointments at 8 wks and 6 months.
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group received ward visits, three telephone calls at home, and clinic appointments at 8 wks and 6 months.
Number of subjects: 126
Study: 10871146

Group type: EXPERIMENTAL
Intervention: Continuous wattage ultrasound (CWUS) at 3 MHz, 1.25 W/cm2 combined with stretching
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham continuous wattage ultrasound combined with stretching
Number of subjects: 21
Study: 9029265

Group type: EXPERIMENTAL
Intervention: Crude tissue section lysates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Purified DNA samples
Number of subjects: 0
Study: 1508060

Group type: EXPERIMENTAL
Intervention: SHD 386L
Number of subjects: 45

Group type: COMPARATOR
Intervention: Levonorgestrel alone (Control)
Number of subjects: 45
Study: 6652480

Group type: EXPERIMENTAL
Intervention: Directional advance information (DAI) about the voluntary movement that had to be performed, specifically precuing an extension movement.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Warning signal precuing a flexion movement.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Warning signal precuing an extension movement.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fast-performing subjects compared to slow-performing subjects.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: EMG activity recorded between 20 and 80 ms after the stretch started.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Time course of M3 response to stretch.
Number of subjects: 9
Study: 30272584

Group type: EXPERIMENTAL
Intervention: Gaviscon Double Action (Gaviscon DA)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 424
Study: 30557377

Group type: EXPERIMENTAL
Intervention: Neuromuscular blockade (NMB) infusion for 24 hours
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo infusion for 24 hours
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: NMB infusion
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 81
Study: 27803393

Group type: EXPERIMENTAL
Intervention: Elevated serum levels of hsCRP
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Carotid narrowing over 50% and hsCRP levels >0.29 mg/dL
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Combined assessment of carotid stenosis and hsCRP
Number of subjects: 1065
Study: 24671507

Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg oral daily plus bicalutamide 50 mg oral daily (Arm A)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Bicalutamide 50 mg oral daily alone (Arm B)
Number of subjects: 39
Study: 22364395

Group type: EXPERIMENTAL
Intervention: Dynamic auditory information about the object's trajectory
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Continuous sound with no information about the object's location
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Discontinuous auditory information or auditory information dislocated relative to vision
Number of subjects: 72
Study: 20855048

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy for Adolescents (PE‐A)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Time-Limited Dynamic Therapy for Adolescents (TLDP‐A)
Number of subjects: 38
Study: 17661955

Group type: EXPERIMENTAL
Intervention: Desipramine 100 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin 1,800 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg/d
Number of subjects: 0
Study: 16305870

Group type: EXPERIMENTAL
Intervention: Pulmonary autografts
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mechanical valve (Edwards MIRA)
Number of subjects: 40
Study: 12413112

Group type: EXPERIMENTAL
Intervention: 24% oxygen supply (experimental group)
Number of subjects: 201

Group type: COMPARATOR
Intervention: 100% oxygen supply (control group)
Number of subjects: 201
Study: 10214833

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 8

Group type: COMPARATOR
Intervention: HRT
Number of subjects: 8

Group type: COMPARATOR
Intervention: Estrogen
Number of subjects: 8
Study: 7601950

Group type: EXPERIMENTAL
Intervention: 0.05% desonide ointment
Number of subjects: 113

Group type: COMPARATOR
Intervention: 1% hydrocortisone ointment
Number of subjects: 113
Study: 2082488

Group type: EXPERIMENTAL
Intervention: Aspirin-dipyridamole combination
Number of subjects: 376

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study: 582746

Group type: EXPERIMENTAL
Intervention: 3 X 1 mg difenoxin hydrochloride (Lyspafen)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31084684

Group type: EXPERIMENTAL
Intervention: Mobile Air‐Smart Spirometer
Number of subjects: 200

Group type: COMPARATOR
Intervention: Desktop Spirometer
Number of subjects: 200
Study: 28288407

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 220

Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 220
Study: 24297636

Group type: EXPERIMENTAL
Intervention: LigaSure vessel-sealing system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional technique (Control)
Number of subjects: 40
Study: 23927461

Group type: EXPERIMENTAL
Intervention: Combined hydroxyurea (HU) and recombinant human erythropoietin (rHuEPO)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Single hydroxyurea (HU) therapy
Number of subjects: 80
Study: 21830417

Group type: EXPERIMENTAL
Intervention: PlasmaJet (5mL)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Fibrin glue (Tissucol)
Number of subjects: 58
Study: 19858327

Group type: EXPERIMENTAL
Intervention: Resistance exercise with mirrors
Number of subjects: 32

Group type: COMPARATOR
Intervention: Resistance exercise without mirrors
Number of subjects: 32
Study: 16429701

Group type: EXPERIMENTAL
Intervention: Tyrian SPE
Number of subjects: 30

Group type: COMPARATOR
Intervention: Prime & Bond NT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AdheSE
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AdheSE and Clearfil SE Bond
Number of subjects: 30
Study: 15613919

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg
Number of subjects: 113

Group type: COMPARATOR
Intervention: Conjugated equine estrogen/medroxyprogesterone acetate
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 113
Study: 11320043

Group type: EXPERIMENTAL
Intervention: rhG‐CSF (10 microg/kg/day) administered intravenously
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 9300214

Group type: EXPERIMENTAL
Intervention: Peer presence and personal factors (4 personal factors assessed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-regulation model (SRM) variables (ability beliefs, preference for thrill seeking, peer nomination, competitiveness, interest)
Number of subjects: 0